Your browser is no longer supported. Please, upgrade your browser.
BLUE bluebird bio, Inc. daily Stock Chart
BLUE [NASD]
bluebird bio, Inc.
Index- P/E- EPS (ttm)-12.99 Insider Own0.20% Shs Outstand55.29M Perf Week13.01%
Market Cap4.96B Forward P/E- EPS next Y-14.69 Insider Trans-17.58% Shs Float55.06M Perf Month16.86%
Income-715.30M PEG- EPS next Q-3.72 Inst Own- Short Float14.77% Perf Quarter-16.01%
Sales53.90M P/S92.07 EPS this Y-5.30% Inst Trans3.66% Short Ratio7.36 Perf Half Y-26.85%
Book/sh26.62 P/B3.37 EPS next Y-4.90% ROA-34.50% Target Price142.94 Perf Year-11.93%
Cash/sh21.34 P/C4.21 EPS next 5Y- ROE-42.30% 52W Range71.42 - 163.43 Perf YTD-9.53%
Dividend- P/FCF- EPS past 5Y-39.60% ROI-28.10% 52W High-45.08% Beta2.35
Dividend %- Quick Ratio6.20 Sales past 5Y22.00% Gross Margin- 52W Low25.67% ATR4.84
Employees1012 Current Ratio6.20 Sales Q/Q-22.60% Oper. Margin- RSI (14)61.45 Volatility9.47% 5.70%
OptionableYes Debt/Eq0.00 EPS Q/Q-36.50% Profit Margin- Rel Volume2.09 Prev Close84.05
ShortableYes LT Debt/Eq0.00 EarningsNov 07 AMC Payout- Avg Volume1.10M Price89.75
Recom1.90 SMA2014.44% SMA509.30% SMA200-23.30% Volume2,313,588 Change6.78%
Dec-13-19Upgrade Oppenheimer Perform → Outperform $135
Nov-26-19Upgrade SVB Leerink Mkt Perform → Outperform $119
Nov-19-19Downgrade Evercore ISI Outperform → In-line $86
Nov-04-19Upgrade Wedbush Neutral → Outperform $131 → $124
Oct-01-19Initiated Stifel Hold $109
Aug-12-19Downgrade William Blair Outperform → Mkt Perform
Jun-18-19Upgrade Maxim Group Hold → Buy $160
May-15-19Downgrade Wedbush Outperform → Neutral $166 → $131
Mar-05-19Downgrade SVB Leerink Outperform → Mkt Perform
Feb-22-19Reiterated Cantor Fitzgerald Neutral $134 → $122
Dec-20-18Initiated Raymond James Strong Buy $165
Dec-06-18Downgrade Piper Jaffray Overweight → Neutral
Nov-14-18Upgrade Bernstein Mkt Perform → Outperform
Nov-05-18Upgrade Janney Neutral → Buy
Nov-02-18Upgrade Cantor Fitzgerald Underweight → Neutral $122 → $134
Jul-12-18Initiated Gabelli & Co Buy $239
Jun-19-18Upgrade Evercore ISI In-line → Outperform
Mar-21-18Reiterated Morgan Stanley Equal-Weight $152 → $209
Mar-14-18Initiated Janney Neutral
Mar-05-18Initiated William Blair Outperform
Dec-12-19 07:34AM  Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting MarketWatch
Dec-11-19 12:16PM  Is bluebird bio Inc (BLUE) Going to Burn These Hedge Funds? Insider Monkey
09:41AM  Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar Zacks
08:59AM  Bluebird bio Is Remarkably Undervalued, Analyst Says Barrons.com
Dec-10-19 09:48AM  Fate (FATE) Announces Encouraging Data on Immunotherapies Zacks +11.87%
Dec-09-19 06:15PM  bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition Business Wire
04:30PM  bluebird bio Presents New Data Demonstrating Long-Term Transfusion Independence and Safety for LentiGlobin Gene Therapy for -thalassemia (betibeglogene autotemcel) at 61st ASH Annual Meeting and Exposition Business Wire
04:03PM  bluebird Reports Positive Top-Line Data on Myeloma Drug Zacks
03:51PM  5 Top Stock Trades for Tuesday: CHWY, SFIX, SHOP InvestorPlace
09:16AM  Bluebird Bio Stock Is Rising on Promising Cancer-Drug Data Barrons.com
Dec-07-19 02:00PM  bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition Business Wire
Dec-06-19 04:30PM  Bluebird, Celgene Cancer Therapy Gets Boost From New Study Bloomberg
04:16PM  Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Business Wire
09:15AM  Stocks Rebound and Hang Onto Recent Gains Zacks
Dec-03-19 08:52AM  Are Options Traders Betting on a Big Move in bluebird (BLUE) Stock? Zacks +5.77%
Dec-02-19 07:30AM  bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting Business Wire
Nov-27-19 03:28AM  Global Blood's (GBT) Oxbryta Secures FDA Approval for SCD Zacks +7.01%
Nov-26-19 09:19AM  Bluebird Bio Stock Is Rising as Analyst Cites Room for Gains Barrons.com
Nov-19-19 10:46AM  CRISPR Therapeutics stock jumps on early gene editing data American City Business Journals
Nov-18-19 09:36AM  Novartis Receives FDA Nod for Adakveo in Sickle Cell Disease Zacks
Nov-12-19 07:00AM  bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy Business Wire
Nov-08-19 02:20PM  FDA approves Acceleron's blood disorder drug ahead of schedule American City Business Journals
Nov-07-19 06:08AM  These 36 Mass. firms made Deloitte's Technology Fast 500 American City Business Journals
Nov-06-19 09:00AM  bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition Business Wire
Nov-05-19 08:58AM  Euphoric investors trigger alarm bells over stock market rally MarketWatch
Nov-03-19 08:03AM  Companies Like bluebird bio (NASDAQ:BLUE) Are In A Position To Invest In Growth Simply Wall St.
Nov-02-19 12:00PM  What Does A Double Bottom Base Look Like? This Top Biotech Stock Formed A Great One Investor's Business Daily
Oct-31-19 05:35PM  Bluebird Bio (BLUE) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM  bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress Business Wire
10:33AM  Analysts Estimate Bluebird Bio (BLUE) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-23-19 04:30PM  bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh Business Wire
Oct-22-19 07:30AM  European Medicines Agency Approves Refined Commercial Manufacturing Specifications for ZYNTEGLO Business Wire
Oct-18-19 11:22AM  New Gilead CFO: Let's Make a Deal GuruFocus.com
Oct-15-19 11:01AM  Is bluebird bio Inc (BLUE) Going To Burn These Hedge Funds ? Insider Monkey
Oct-11-19 12:49PM  Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment Zacks
Oct-10-19 11:17AM  bluebird Inks Genome Editing Research Deal With Novo Nordisk Zacks
Oct-09-19 08:00AM  bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases Business Wire
Oct-03-19 03:02PM  3 Cancer-Fighting Drug Stocks to Buy Right Now InvestorPlace
Oct-01-19 01:48PM  Stifel Bullish On Iovance And Fate Therapeutics, Neutral On Bluebird Bio Benzinga -5.23%
05:52AM  LabCentral gets state, private funds for new biomanufacturing lab space American City Business Journals
Sep-27-19 07:00AM  bluebird bio Appoints William R. Sellers, M.D. to Board of Directors Business Wire
Sep-19-19 09:57AM  Is There An Opportunity With bluebird bio, Inc.'s (NASDAQ:BLUE) 48% Undervaluation? Simply Wall St.
Sep-18-19 09:25AM  bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress Business Wire
Sep-09-19 01:33PM  Here's Why bluebird bio Fell 21.3% in August Motley Fool
Sep-06-19 11:53AM  FDA Grants Priority Review to Global Blood's SCD Candidate Zacks
Aug-31-19 09:31AM  Bluebird (BLUE) Down 19.4% Since Last Earnings Report: Can It Rebound? Zacks
Aug-22-19 04:05PM  bluebird bio Announces Investor Events in September Business Wire -7.29%
02:18AM  Massachusetts-based biotech company opens office in Eastlake neighborhood (Photos) American City Business Journals
Aug-16-19 06:20AM  Gene therapies to test FDA's approach to regulating drugs after launch, experts say American City Business Journals
Aug-12-19 04:16PM  Why This Biotech's $1.8 Million Gene Therapy Could Be A 'Slow Mover' Investor's Business Daily -5.25%
10:30AM  Bluebird Bio Stock Down as Analyst Raises Worries About Zynteglo Launch Barrons.com
07:38AM  Bluebird Bio Drops Following William Blair Downgrade TheStreet.com
Aug-08-19 10:25AM  Did bluebird bio, Inc. (NASDAQ:BLUE) Insiders Sell Shares? Simply Wall St.
Aug-07-19 05:30PM  bluebird bio Prepares for Launch Motley Fool
Aug-02-19 11:12AM  bluebird's (BLUE) Loss Wider Than Expected, Revenues Beat Zacks -6.14%
Aug-01-19 07:45PM  Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:36PM  bluebird bio Reports Second Quarter 2019 Financial Results and Highlights Operational Progress Business Wire
Jul-25-19 10:33AM  Analysts Estimate Bluebird Bio (BLUE) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-15-19 02:46PM  Biotech investors Wellington, RA Capitals new funds top $700 million American City Business Journals
Jul-10-19 05:43AM  JP Morgan: 2 Gene Therapy Stocks to Buy Now TipRanks
Jul-09-19 01:58PM  5 Immunotherapy Stocks to Keep a Close Eye On GuruFocus.com
Jul-07-19 12:13PM  Is bluebird bio a Buy? Motley Fool
Jul-02-19 11:53AM  Marshall Waces Return, AUM, and Holdings (Part II) Insider Monkey
Jun-21-19 08:00AM  Where Will bluebird bio Be in 1 Year? Motley Fool
Jun-18-19 04:14PM  Why This Biotech's Approved Gene Therapy Won't Launch Until 2020 Investor's Business Daily
09:53AM  Bluebird Bio Stock Rises on Analysts Buy Call Barrons.com
Jun-17-19 07:17PM  Is bluebird bio Inc (BLUE) A Good Stock To Buy? Insider Monkey
Jun-15-19 05:00PM  Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous? Motley Fool
Jun-14-19 04:00PM  Bluebird Bios Gene Therapy Is $1.8 Million Per Patient. The Stock Is Falling. Barrons.com -5.07%
08:54AM  Bluebird prices gene therapy in Europe at $1.8M over 5 years American City Business Journals
05:31AM  bluebird bio Presents New Data for LentiGlobin® Gene Therapy for Sickle Cell Disease (SCD) at 24th European Hematology Association (EHA) Congress Business Wire
05:31AM  bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent -Thalassemia (TDT) at 24th European Hematology Association (EHA) Congress Business Wire
Jun-13-19 10:35PM  Bluebird Bio prices gene therapy at nearly $1.8m Financial Times +5.52%
09:08PM  Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license American City Business Journals
Jun-12-19 12:14PM  bluebird bio (NASDAQ:BLUE) Shareholders Have Enjoyed An Impressive 223% Share Price Gain Simply Wall St.
Jun-06-19 05:04PM  bluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® (autologous CD34+ cells encoding A-T87Q-globin gene) Approval Business Wire
09:17AM  Life sciences VC firm Third Rock raises $770M in its largest round ever American City Business Journals
Jun-04-19 04:16PM  bluebird's Zynteglo Gets EU Conditional Marketing Approval Zacks +5.73%
03:31PM  It's Official: bluebird bio Gets a Green Light for Game-Changing Gene Therapy Motley Fool
Jun-03-19 09:25AM  bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO (autologous CD34+ cells encoding A-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent -Thalassemia Who Do Not Have 0/0 Genotype Business Wire
Jun-01-19 09:31AM  Why Is Bluebird (BLUE) Down 15.1% Since Last Earnings Report? Zacks
May-31-19 08:00AM  bluebird bio Announces Investor Events in June Business Wire
May-30-19 02:34PM  Save the Date: 11 Biotech Stocks to Put on Your Radar Kiplinger
May-25-19 12:30PM  Marshall Waces Latest Moves Insider Monkey
May-19-19 07:00AM  Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big Motley Fool
May-16-19 09:12AM  bluebird bio to Present New Data from Clinical Studies of LentiGlobin Gene Therapy for Transfusion-Dependent -thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at the 24th EHA Congress Business Wire
May-15-19 02:10PM  Bluebird Bio's Near-Term Product Launches Pose Risks, Wedbush Says In Downgrade Benzinga
10:49AM  Bluebird Bios Pricing Plan Worries One Biotech Analyst. Heres Why. Barrons.com
May-09-19 06:30AM  bluebird bios Analyst Day Highlights Commercial Path to Patients and Research Engine Focused on Next-Generation Gene and Cell Therapies Business Wire
May-08-19 08:12AM  bluebird bio Flies Forward Motley Fool
May-06-19 11:50AM  bluebird's (BLUE) Loss Wider Than Expected, Revenues Down Y/Y Zacks
May-03-19 08:00AM  bluebird bio Announces Investor Events in May Business Wire
May-02-19 06:45PM  Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates Zacks
05:40PM  Bluebird: 1Q Earnings Snapshot Associated Press
04:05PM  bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress Business Wire
May-01-19 05:01PM  Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine Business Wire
08:00AM  bluebird bio Appoints Joanne Smith-Farrell, Ph.D., to Chief Business Officer Business Wire
Apr-30-19 03:18PM  5 Biotech Stocks for a Long-Lived Portfolio InvestorPlace
09:15AM  Small Gains Still Bring New Highs Zacks
Apr-29-19 08:01AM  20 High-Growth Stocks For The Next 20 Years Motley Fool
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gregory Philip DChief Scientific OfficerDec 05Sale80.5725020,14329,092Dec 09 05:01 PM
Gregory Philip DChief Scientific OfficerNov 05Sale81.9525020,48829,342Nov 07 04:11 PM
Gregory Philip DChief Scientific OfficerOct 07Sale89.0725022,26729,592Oct 09 04:14 PM
Davidson DavidChief Medical OfficerSep 10Option Exercise50.512,060104,05133,676Sep 11 04:29 PM
Davidson DavidChief Medical OfficerSep 10Sale100.162,060206,32431,616Sep 11 04:29 PM
Davidson DavidChief Medical OfficerSep 09Option Exercise50.513,000151,53034,616Sep 11 04:29 PM
Davidson DavidChief Medical OfficerSep 09Sale100.113,000300,34031,616Sep 11 04:29 PM
Gregory Philip DChief Scientific OfficerSep 05Option Exercise50.5160030,30630,692Sep 09 04:54 PM
Gregory Philip DChief Scientific OfficerSep 05Sale101.2085086,01829,842Sep 09 04:54 PM
Walsh Jeffrey T.Chief Strategy OfficerAug 20Option Exercise24.4750012,23541,421Aug 21 04:06 PM
Walsh Jeffrey T.Chief Strategy OfficerAug 20Sale124.0050062,00040,921Aug 21 04:06 PM
Gregory Philip DChief Scientific OfficerAug 08Option Exercise75.6070052,92031,042Aug 12 04:08 PM
Gregory Philip DChief Scientific OfficerAug 08Sale124.03950117,82430,092Aug 12 04:08 PM
Davidson DavidChief Medical OfficerAug 06Option Exercise50.515,060255,58136,676Aug 08 04:19 PM
Davidson DavidChief Medical OfficerAug 06Sale116.085,060587,38931,616Aug 08 04:19 PM
Gregory Philip DChief Scientific OfficerAug 05Option Exercise50.5160030,30631,192Aug 07 04:14 PM
Gregory Philip DChief Scientific OfficerAug 05Sale116.9385099,39330,342Aug 07 04:14 PM
Davidson DavidChief Medical OfficerJul 05Option Exercise48.577,660372,05339,276Jul 09 04:20 PM
Gregory Philip DChief Scientific OfficerJul 05Option Exercise64.021,30083,22632,392Jul 09 04:22 PM
Gregory Philip DChief Scientific OfficerJul 05Sale129.131,800232,42630,592Jul 09 04:22 PM
Davidson DavidChief Medical OfficerJul 05Sale129.477,660991,74831,616Jul 09 04:20 PM
Walsh Jeffrey T.Chief Strategy OfficerJun 18Option Exercise24.471002,44741,021Jun 20 04:52 PM
Walsh Jeffrey T.Chief Strategy OfficerJun 18Sale126.1210012,61240,921Jun 20 04:52 PM
Walsh Jeffrey T.Chief Strategy OfficerJun 10Option Exercise24.471,40034,25842,321Jun 12 04:31 PM
Walsh Jeffrey T.Chief Strategy OfficerJun 10Sale125.441,400175,61940,921Jun 12 04:31 PM
Davidson DavidChief Medical OfficerJun 06Option Exercise50.515,060255,58136,676Jun 10 04:14 PM
Davidson DavidChief Medical OfficerJun 06Sale122.645,060620,53931,616Jun 10 04:14 PM
Gregory Philip DChief Scientific OfficerJun 05Option Exercise64.021,30083,22632,892Jun 07 04:09 PM
WENTWORTH KORY JAMESPrincipal Accounting OfficerJun 05Sale127.60617,7846,846Jun 07 04:11 PM
Gregory Philip DChief Scientific OfficerJun 05Sale128.601,800231,48831,092Jun 07 04:09 PM
Walsh Jeffrey T.Chief Strategy OfficerMay 10Option Exercise24.471,50036,70542,421May 14 04:08 PM
Cole JasonChief Operating andMay 10Option Exercise50.5156228,38727,006May 14 04:07 PM
Walsh Jeffrey T.Chief Strategy OfficerMay 10Sale132.301,500198,45040,921May 14 04:08 PM
Davidson DavidChief Medical OfficerMay 06Option Exercise5.506,36034,98337,976May 08 04:35 PM
Gregory Philip DChief Scientific OfficerMay 06Option Exercise64.021,30083,22633,392May 08 04:35 PM
Gregory Philip DChief Scientific OfficerMay 06Sale138.441,800249,18331,592May 08 04:35 PM
Davidson DavidChief Medical OfficerMay 06Sale138.956,360883,71831,616May 08 04:35 PM
Walsh Jeffrey T.Chief Strategy OfficerApr 10Option Exercise24.471,50036,70542,421Apr 12 04:17 PM
Walsh Jeffrey T.Chief Strategy OfficerApr 10Sale156.651,500234,97640,921Apr 12 04:17 PM
Gregory Philip DChief Scientific OfficerApr 05Option Exercise64.021,30083,22633,892Apr 09 04:50 PM
Gregory Philip DChief Scientific OfficerApr 05Sale157.601,800283,68132,092Apr 09 04:50 PM
Davidson DavidChief Medical OfficerApr 04Option Exercise5.506,36034,98337,976Apr 08 04:11 PM
Davidson DavidChief Medical OfficerApr 04Sale160.066,3601,017,97631,616Apr 08 04:11 PM
Davidson DavidChief Medical OfficerMar 13Option Exercise5.503,10117,05734,717Mar 15 04:32 PM
Davidson DavidChief Medical OfficerMar 13Sale146.413,101454,00531,616Mar 15 04:32 PM
Walsh Jeffrey T.Chief Strategy OfficerMar 11Option Exercise24.471,50036,70542,421Mar 13 04:14 PM
Walsh Jeffrey T.Chief Strategy OfficerMar 11Sale139.801,500209,69840,921Mar 13 04:14 PM
Gregory Philip DChief Scientific OfficerMar 05Option Exercise64.021,30083,22634,392Mar 07 04:26 PM
Gregory Philip DChief Scientific OfficerMar 05Sale147.711,800265,87932,592Mar 07 04:26 PM
Davidson DavidChief Medical OfficerMar 04Option Exercise50.514,910248,00436,526Mar 06 04:32 PM
Davidson DavidChief Medical OfficerMar 04Sale155.774,910764,83231,616Mar 06 04:32 PM
WENTWORTH KORY JAMESPrincipal Accounting OfficerFeb 28Sale151.71517,7376,695Mar 04 04:34 PM
Cole JasonChief Operating andFeb 25Option Exercise40.446,248252,68732,692Feb 27 04:59 PM
Cole JasonChief Operating andFeb 25Sale150.246,248938,69826,444Feb 27 04:59 PM
WENTWORTH KORY JAMESPrincipal Accounting OfficerFeb 25Sale150.0020831,2016,746Feb 27 04:57 PM
Walsh Jeffrey T.Chief Financial andFeb 08Option Exercise24.471,50036,70542,421Feb 12 04:11 PM
Walsh Jeffrey T.Chief Financial andFeb 08Sale131.291,500196,92840,921Feb 12 04:11 PM
Gregory Philip DChief Scientific OfficerFeb 05Option Exercise64.021,30083,22634,892Feb 07 05:21 PM
Gregory Philip DChief Scientific OfficerFeb 05Sale137.991,800248,38333,092Feb 07 05:21 PM
Davidson DavidChief Medical OfficerFeb 04Option Exercise31.664,910155,43236,526Feb 05 05:58 PM
Davidson DavidChief Medical OfficerFeb 04Sale134.304,910659,41731,616Feb 05 05:58 PM
WENTWORTH KORY JAMESPrincipal Accounting OfficerJan 28Sale125.9620926,3264,403Jan 30 04:35 PM
Davidson DavidChief Medical OfficerJan 18Option Exercise24.472,03549,79624,276Jan 23 04:18 PM
Davidson DavidChief Medical OfficerJan 18Sale130.052,035264,64422,241Jan 23 04:18 PM
Gregory Philip DChief Scientific OfficerJan 16Option Exercise75.601,400105,84028,742Jan 18 04:03 PM
Walsh Jeffrey T.Chief FinancialJan 16Option Exercise24.473,00073,41035,483Jan 18 04:06 PM
Walsh Jeffrey T.Chief FinancialJan 16Sale125.143,000375,42832,483Jan 18 04:06 PM
Gregory Philip DChief Scientific OfficerJan 16Sale124.251,900236,06926,842Jan 18 04:03 PM
Gregory Philip DChief Scientific OfficerJan 07Option Exercise50.5160030,30631,221Jan 09 04:57 PM
Walsh Jeffrey T.Chief FinancialJan 07Sale113.643,012342,27632,483Jan 09 05:05 PM
Leschly NickPresident and CEOJan 07Sale113.647,374837,966193,203Jan 09 05:03 PM
Gregory Philip DChief Scientific OfficerJan 07Sale112.493,879436,36327,342Jan 09 04:57 PM
FINGER ALISON CECILYChief Commercial OfficerJan 07Sale113.6464373,06814,548Jan 09 04:53 PM
Davidson DavidChief Medical OfficerJan 07Sale113.642,664302,73422,241Jan 09 04:46 PM
Cole JasonChief Legal OfficerJan 07Sale113.641,416160,91420,194Jan 09 04:39 PM
Davidson DavidChief Medical OfficerJan 03Option Exercise24.471002,44725,005Jan 04 04:17 PM
FINGER ALISON CECILYChief Commercial OfficerJan 03Sale99.3142842,50615,239Jan 07 04:39 PM
Davidson DavidChief Medical OfficerJan 03Sale100.3210010,03224,905Jan 04 04:17 PM
Davidson DavidChief Medical OfficerJan 02Option Exercise17.397,500130,41029,605Jan 04 04:17 PM
Davidson DavidChief Medical OfficerJan 02Sale98.807,500741,02824,905Jan 04 04:17 PM
WENTWORTH KORY JAMESPrincipal Accounting OfficerDec 19Sale103.0538839,9834,612Dec 21 04:26 PM